← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,625	+21	+1%	$21.3B
2	2 Charles River Laboratories CRL $14.4B	570	+10	+2%	$12.9B
3	3 CRISPR Therapeutics CRSP $4.86B	524	+32	+7%	$4.16B
4	4 BridgeBio Pharma BBIO $12.7B	475	+13	+3%	$14.4B
5	5 Krystal Biotech KRYS $9.79B	423	+55	+15%	$11.1B
6	6 PTC Therapeutics PTCT $4.98B	382	+30	+9%	$8.2B
7	7 Intellia Therapeutics NTLA $1.6B	328	+24	+8%	$2.44B
8	8 Sarepta Therapeutics SRPT $1.78B	324	-21	-6%	$1.93B
9	9 Vericel Corp VCEL $2.06B	320	+40	+14%	$2.47B
10	10 Ultragenyx Pharmaceutical RARE $1.47B	311	+13	+4%	$3.55B
11	11 uniQure QURE $1.45B	254	+40	+19%	$3.02B
12	12 Legend Biotech LEGN $3.7B	219	+29	+15%	$2.98B
13	13 DELISTED BioLife Solutions BLFS	216	+29	+16%	$1.4B
14	14 Sana Biotechnology SANA $698M	211	+8	+4%	$644M
15	15 Precigen PGEN $2.64B	210	+4	+2%	$799M
16	16 Allogene Therapeutics ALLO $449M	209	0	0%	$652M
17	17 Taysha Gene Therapies TSHA $1.14B	208	+17	+9%	$2.06B
18	18 Prime Medicine PRME $568M	187	-5	-3%	$393M
19	19 Rocket Pharmaceuticals RCKT $243M	180	-19	-10%	$341M
20	20 Capricor Therapeutics CAPR $383M	169	-8	-5%	$942M
21	21 Regenxbio RGNX $454M	165	-13	-7%	$505M
22	22 MeiraGTx Holdings MGTX $904M	158	+25	+19%	$1.07B
23	23 4D Molecular Therapeutics FDMT $674M	157	+4	+3%	$771M
24	24 Fate Therapeutics FATE $232M	156	-2	-1%	$193M
25	25 Solid Biosciences SLDB $585M	156	+6	+4%	$1.14B